PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Approximately 25 subjects will be enrolled and receive a standard WHO adult potency BCG immunization (1cc/50mg live mycobacilli) in the deltoid. Following a wait period after BCG vaccination, patients will then receive standard strength BCG intravesical therapy once a week for a total of 6 weeks. The BCG is instilled and held in the bladder for approximately 2 hours. While the BCG is retained in the bladder the patient should be repositioned every 30 minutes to maximize bladder surface exposure to the agent. Patients will undergo a cystoscopy every 3 months following most recent TURBT. Study duration last approximately 6 months.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The University of Texas Health Science Center at San Antonio
• Treatments: BCG Vaccine; Vaccines

Criteria

Inclusion Criteria:

The patient must:

• Be 18 years of age or older

• Be able to give informed consent

• Have newly diagnosed or recurrent multi-focal Ta, Large Ta, High Grade Ta, CIS or T1 Bladder Cancer

• Determined by treating urologist to be a good candidate for BCG Induction Therapy

• Have an adequate marrow function (defined as white blood cells greater than 1.5 x 103/µl (or 1,500 cells/mm3) and platelets greater than 150,000 cells/mm3; these results can be within last 60 days from the day of signing informed consent

Exclusion Criteria:

The patient cannot:

• Be less than18 years of age

• Unable to give informed consent

• Have a history of muscle invasive bladder cancer

• Be self-reported to be immune-compromised (HIV, chronic immunomodulators, chronic corticosteroids)

• Have a history of tuberculosis and/or received BCG Percutaneous Vaccination

• Pregnant or planning to become pregnant.